Ideaya Biosciences

Ideaya Biosciences

Yahoo Finance • 9 days ago

IDEAYA's Board Of Directors Elect Hata As Chairman Of Board

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a clinical-stage oncology company, on Tuesday announced the appointment of Yujiro S. Hata as Chairman of the Board by its Board of Directors. Hata currently serves as the President and Chief Ex... Full story

Yahoo Finance • 15 days ago

Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study

IDEAYA Biosciences Inc. (NASDAQ:IDYA) is one of the 10 best AI driven biotech stocks to invest in. On June 3, in order to study the safety and efficacy of IDE892 in conjunction with Roche’s pan-RAS inhibitor, RG6505, in patients with MTAP... Full story

Yahoo Finance • 17 days ago

Biggest stock movers Tuesday: APLD, QCOM, and more

[glowing graph 2] Jonathan Kitchen Stock futures rose slightly, and crude oil benchmark prices fell on Tuesday morning as geopolitical anxieties showed signs of easing. Here are some of Tuesday's biggest stock movers: BIGGEST STOCK GAIN... Full story

Yahoo Finance • 20 days ago

What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders

IDEAYA Biosciences recently reported full Phase 2/3 OptimUM-02 data showing its darovasertib and crizotinib combination improved progression-free survival and response rates versus standard therapies in first-line HLA*A2:01 negative metast... Full story

Yahoo Finance • 23 days ago

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutan... Full story

Yahoo Finance • 2 months ago

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO IDEAYA to initiate RTOR submission process with first pre-submiss... Full story

Yahoo Finance • 2 months ago

Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?

Is IDYA a good stock to buy? We came across a bullish thesis on IDEAYA Biosciences, Inc. on Valueinvestorsclub.com by pestopenguin. In this article, we will summarize the bulls’ thesis on IDYA. IDEAYA Biosciences, Inc.'s share was trading... Full story

Yahoo Finance • 2 months ago

Stocks Settle Higher in Hopes for an Agreement to End the Iran War

The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.02%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.63%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.06%.  June E-mini S&P futures (ESM26) rose +0.98%, and June E-m... Full story

Yahoo Finance • 2 months ago

Stocks Recover as Oracle Leads Software Companies Higher

The S&P 500 Index ($SPX) (SPY) today is up +0.09%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.39%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.16%.  June E-mini S&P futures (ESM26) are up +0.12%, and June E-mini Nasdaq f... Full story

Yahoo Finance • 2 months ago

Stocks Mixed as US Set to Blockade the Strait of Hormuz

The S&P 500 Index ($SPX) (SPY) today is up +0.05%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.39%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.21%. Stock indexes are mixed this morning even as crude oil prices surge aft... Full story

Yahoo Finance • 3 months ago

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a confe... Full story

Yahoo Finance • 3 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and K... Full story

Yahoo Finance • 3 months ago

Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Uveal Neoplasms Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global uveal neoplasms market has demonstrated robust growth, with projections indicating a ri... Full story

Yahoo Finance • 3 months ago

IDEAYA slips on delaying results from darovasertib uveal melanoma trial

[Close up of the eye with carcinoma] flik47/iStock via Getty Images * IDEAYA Biosciences (IDYA [https://seekingalpha.com/symbol/IDYA]) is down ~5% in Monday trading after announcing it is delaying the release of topline results from a p... Full story

Yahoo Finance • 3 months ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story

Yahoo Finance • 4 months ago

IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the 10 Fastest Growing NASDAQ Stocks to Buy.IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC On February 25, 2026, IDEAYA Biosciences, Inc. (NA... Full story

Yahoo Finance • 4 months ago

Notable Thursday Option Activity: MDB, SOC, IDYA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MongoDB Inc (Symbol: MDB), where a total of 34,692 contracts have traded so far, representing approximately 3.5 million underlying... Full story

Yahoo Finance • 6 months ago

Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers

(RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. Novo Nordisk A/S (NVO) surged in extended trading, climbing 9.48% t... Full story

Yahoo Finance • 6 months ago

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the Unite... Full story

Yahoo Finance • 7 months ago

IDEAYA Secures IND Clearance For IDE034 In Solid Tumors

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), announced that the U.S. FDA has cleared its IND application for IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody-drug conjugate (ADC) for the treatment of multiple solid tum... Full story